M&A Deal Summary

Johnson & Johnson Acquires V-Wave

On October 9, 2024, Johnson & Johnson acquired medical products company V-Wave

Acquisition Highlights
  • This is Johnson & Johnson’s 17th transaction in the Medical Products sector.
  • This is Johnson & Johnson’s 1st transaction in Israel.

M&A Deal Summary
Date 2024-10-09
Target V-Wave
Sector Medical Products
Buyer(s) Johnson & Johnson
Deal Type Add-on Acquisition

Target

V-Wave

Caesarea, Israel
V-Wave develops percutaneous implantable technologies for patients with chronic heart failure. V-Wave was formed in 2009 and is headquartered in Caesarea, Israel.

Search 200,577 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Johnson & Johnson

New Brunswick, New Jersey, United States
Category Company
Founded 1886
Sector Consumer Products
Employees132,000
Revenue 85.2B USD (2023)
DESCRIPTION
Johnson & Johnson's corporate headquarters in New Brunswick, New Jersey.
Johnson & Johnson's corporate headquarters in New Brunswick, New Jersey.

Johnson & Johnson is a global healthcare conglomerate that operates across three primary sectors: Pharmaceuticals, Medical Devices, and Consumer Health. In Pharmaceuticals, it develops treatments for a variety of conditions, including immunology, oncology, and infectious diseases. The Medical Devices segment offers a range of equipment and devices for healthcare professionals, encompassing orthopedics, surgery, and cardiovascular care. Its Consumer Health division markets a wide array of products, spanning baby care, oral care, skin care, over-the-counter drugs, and women's health, with popular brands such as Band-Aid, Tylenol, and Neutrogena under its umbrella. Johnson & Johnson was formed in 1886 and is based in New Brunswick, New Jersey.

DEAL STATS #
Overall 45 of 45
Sector (Medical Products) 17 of 17
Type (Add-on Acquisition) 36 of 36
Country (Israel) 1 of 1
Year (2024) 4 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2024-05-16 Proteologix

California, United States

Proteologix is a privately held biotechnology company focused on bispecific antibodies for immune-mediated diseases. The company's portfolio includes PX128, a bispecific antibody targeting IL-13 plus TSLP, which is ready to enter phase 1 development for moderate to severe atopic dermatitis (AD) and moderate to severe asthma, and PX130, a bispecific antibody targeting IL-13 plus IL-22, which is in preclinical development for moderate to severe AD. Proteologix is based in California.

Buy $850M
Mergr

Product

Company

Legal